Faraday Pharmaceuticals

Faraday Pharmaceuticals, Inc. was a Seattle, Washington–based clinical-stage biotechnology company focused on reducing damage to cardiac and skeletal muscle following acute critical illness, with the stated goal of improving patients' quality of life after such events [0][1]. Its work centered on drugs to prevent and treat cardiac and skeletal muscle loss [1]. Third-party pipeline databases classify the company under cardiovascular diseases, nervous system diseases and endocrinology/metabolic disease, with small-molecule drugs as its principal modality [2].

The company's lead asset was FDY-5301, an intravenous formulation containing sodium iodide, an inorganic halide and elemental reducing agent described as acting as a catalytic anti-peroxidant to limit ischemia-reperfusion injury [2]. FDY-5301 reached Phase 3 for acute myocardial infarction; other indications listed include musculoskeletal diseases (inactive) [2]. Faraday is also listed as an active organization on S-oxprenolol, a beta-adrenoceptor antagonist at preclinical stage for amyotrophic lateral sclerosis, originated by Actimed Therapeutics, and is associated in the same database with espindolol [2].

Four clinical trials are associated with the company, including the completed Phase 2A study NCT03470441 in STEMI patients undergoing PCI (started October 2017), the terminated Phase 2 study NCT04430283 in ICU-acquired weakness among major trauma patients (started September 2021), and the completed Phase 3 study NCT04837001 in anterior STEMI patients undergoing primary PCI (started May 2022) [2].

Business model

Faraday operated as a clinical-stage drug developer, advancing proprietary small-molecule candidates through company-sponsored clinical trials rather than selling a marketed product; no revenue-generating commercial operations are described in the sources [0][2].

Traction

FDY-5301 advanced through a 120-patient Phase 2 trial randomized at 20 primary PCI centers, in which the drug was delivered before reopening of the infarct-related artery in 97% of participants, no significant increase in the primary cardiac arrhythmia safety endpoint was observed, and exploratory MRI endpoints at three months showed median final infarct size of 8.5% with 2.0 mg/kg FDY-5301 versus 14.9% with placebo and LV ejection fractions of 63.2% versus 53.9% (the study was not powered for statistical significance) [2]. Results were published in the International Journal of Cardiology in January 2022 [2]. The subsequent Phase 3 trial in anterior STEMI completed in late 2025 but did not meet its primary or secondary endpoints [1].

Latest developments

In February 2026 Faraday announced it had ceased operations and was winding down the business, following the late-2025 Phase 3 failure of FDY-5301, which missed both primary and secondary endpoints in anterior STEMI patients undergoing primary PCI. BioSpace listed the company among six biotechs that shut down or began winding down in the first quarter of 2026. Former CEO Steve Hill became interim CEO of Bitterroot Bio in February 2026. [1]